Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how useful vitamin D supplementation is in reducing
the severity of COVID-19 symptoms and the body's inflammatory and infection-fighting response
to COVID-19. Individuals ≥50 years of age and older who are tested for COVID-19 and negative
will be randomized (like flipping a coin) to either daily high dose vitamin D supplementation
(6000 IU vitamin D3/day) vs. standard of care. Those individuals ≥50 years of age or older
who test positive for COVID-19 at baseline will be randomized to bolus vitamin D (20,000
IU/day for 3 days) followed by high dose (6000 IU vitamin D/day) vs. standard of care for 12
months. All participants will receive a multivitamin containing vitamin D.
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of South Carolina
Collaborators:
Grassroots Health Nutrition Institute ZRT Laboratory
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins